Centessa Pharmaceuticals (NASDAQ:CNTA) Hits New 52-Week High – Time to Buy?

Centessa Pharmaceuticals plc (NASDAQ:CNTA)’s share price hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $19.02 and last traded at $19.03, with a volume of 1180915 shares. The stock had previously closed at $17.84.

Wall Street Analysts Forecast Growth

Several research firms recently commented on CNTA. TD Cowen started coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating on the stock. Guggenheim lifted their target price on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $25.83.

Centessa Pharmaceuticals Trading Up 6.7 %

The company’s 50-day moving average price is $16.74 and its 200 day moving average price is $15.30. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The stock has a market cap of $2.51 billion, a PE ratio of -12.44 and a beta of 1.53.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.05. On average, sell-side analysts forecast that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Insider Activity

In related news, CEO Saurabh Saha sold 1,671 shares of the company’s stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $18.24, for a total value of $30,479.04. Following the completion of the sale, the chief executive officer now directly owns 575,661 shares of the company’s stock, valued at $10,500,056.64. This represents a 0.29 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Gregory M. Weinhoff sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $17.66, for a total transaction of $176,600.00. Following the transaction, the insider now owns 183,266 shares in the company, valued at approximately $3,236,477.56. This trade represents a 5.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 421,697 shares of company stock valued at $7,211,475. 11.59% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Centessa Pharmaceuticals by 47.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after acquiring an additional 826 shares during the period. GAMMA Investing LLC boosted its position in Centessa Pharmaceuticals by 103.1% during the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock worth $48,000 after purchasing an additional 1,509 shares in the last quarter. Walleye Capital LLC acquired a new stake in Centessa Pharmaceuticals in the 3rd quarter valued at about $187,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Centessa Pharmaceuticals by 99.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,593 shares of the company’s stock worth $217,000 after purchasing an additional 6,785 shares in the last quarter. Finally, Harbour Capital Advisors LLC acquired a new position in shares of Centessa Pharmaceuticals in the third quarter worth $259,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.